Very early treatment may be key to combatting inherited metabolic disorder

August 4, 2014
This image portrays representative images of GM3 (A–C), LIMP II (D–F), GFAP (G–I), isolectin Bandieraea (Griffonia) simplicifolia (BSI-B4) (J–L) and ubiquitin (M–O) staining in the inferior colliculus of 6-week-old normal (A, D, G, J and M), MPS IIIA (B, E, H, K and N) and MPS IIIA + enzyme-treated (C, F, I, L and O) mice. The rhSGSH injection was administered at 3 weeks of age and images were taken at 3 weeks post-injection, i.e. at 6 weeks of age. Scale bar: image, 50 μm; inset, 5 μm (A–O). Credit: Wiley

A European Journal of Neuroscience study suggests that it is critical to treat lysosomal storage disorders early, before symptoms arise. These genetic disorders, which are caused by the malfunction of enzymes that normally degrade various substances within cells, lead to numerous ailments including neurological problems.

Although few therapeutic options are available, clinical trials of treatments including lysosomal enzyme replacement are underway. Researchers who used enzyme replacement to treat mice with early, mid- and later-stages of a found that treatment was most effecting in mice with very early-stage disease. Once symptoms arose, treatment was ineffective.

"Until is available world-wide for these conditions, and children are diagnosed prior to symptoms appearing, it is critical that we continue to gather information regarding the reversibility, or not, of disease-based degenerative changes," said senior author Dr. Kim Hemsley.

Explore further: New technology for more efficient treatment of Pompe disease, other metabolic disorders

More information: Hassiotis, S., Beard, H., Luck, A., Trim, P. J., King, B., Snel, M. F., Hopwood, J. J. and Hemsley, K. M. (2014), Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease. European Journal of Neuroscience, 39: 2139–2150. DOI: 10.1111/ejn.12557

Related Stories

Infant tests for debilitating diseases set for mainstream

April 2, 2013

(Medical Xpress)—Michael Gelb and František Tureček have worked more than a decade to devise and implement newborn screening for some debilitating, often-fatal conditions that show up in the first year to several years ...

New therapy against rare gene defects

April 15, 2014

On 15th April is the 1st International Pompe Disease Day, a campaign to raise awareness of this rare but severe gene defect. Pompe Disease is only one of more than 40 metabolic disorders that mainly affect children under ...

Recommended for you

Closing the loop with optogenetics

August 28, 2015

An engineering example of closed-loop control is a simple thermostat used to maintain a steady temperature in the home. Without it, heating or air conditioning would run without reacting to changes in outside conditions, ...

Self-control saps memory, study says

August 26, 2015

You're driving on a busy road and you intend to switch lanes when you suddenly realize that there's a car in your blind spot. You have to put a stop to your lane change—and quickly.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.